WaveMan
WaveMan · Company
SLS · Sellas Life Sciences Group, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SLS SELLAS Life Sciences (SLS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001390478
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
139
13F, latest reported quarter

SELLAS Life Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for SELLAS Life Sciences Group, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kalin Katherine Bach
Director
BUY
2025-11-21 SECtraded 2025-11-19
63,400
$100.8K
+644.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 22, 2025.
  • The trade is 60.7% of the 104,400 shares held after it.
  • No other insider bought within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kalin Katherine Bach bought about $100.8K of SLS on Nov 19, 2025, the largest insider purchase at the company on our record; 139 funds added in the latest 13F quarter.
VAN NOSTRAND ROBERT L
Director
BUY
2025-06-13 SECtraded 2025-06-12
10,000
$14.8K
+616.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 49.0% of the 20,400 shares held after it.
  • 2 other insiders bought within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director VAN NOSTRAND ROBERT L bought about $14.8K of SLS on Jun 12, 2025; 2 other insiders bought within 30 days and 139 funds added in the latest 13F quarter.
Wasman Jane
Director
BUY
2025-06-02 SECtraded 2025-05-30
20,000
$33.8K
+603.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 65.8% of the 30,400 shares held after it.
  • 2 other insiders bought within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wasman Jane bought about $33.8K of SLS on May 30, 2025; 2 other insiders bought within 30 days and 139 funds added in the latest 13F quarter.
Kalin Katherine Bach
Director
BUY
2025-05-22 SEC
20,000
$36.0K
+510.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 48.8% of the 41,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kalin Katherine Bach bought about $36.0K of SLS on May 22, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 139 funds added in the latest 13F quarter.
Stergiou Angelos M.
President and CEO
SELL
2022-12-05 SEC
6,494
$16.9K
+374.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 2, 2021.
  • The trade is 4.0% of the 161,689 shares held after it.
  • 2 other insiders sold within 30 days.
  • 139 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Stergiou Angelos M. sold about $16.9K of SLS on Dec 5, 2022, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 139 funds added in the latest 13F quarter.
10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 5 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
139 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
27.4% of the float short (float per yahoo 2026-10-26) · 9.4 days to cover · settled 2026-09-30
more than 99% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SLS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+491.8%12M
-29%+212%+452%+693%2025-102025-122026-022026-042026-062026-082026-10 2025-11-19 · Kalin Katherine Bach bought $100.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SLS: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
15,070,302 sh
$222.4M
STATE STREET CORP
12,996,558 sh
$191.8M
VANGUARD CAPITAL MANAGEMENT LLC
8,226,105 sh
$121.4M
GEODE CAPITAL MANAGEMENT, LLC
4,884,175 sh
$72.1M
Anson Funds Management LP
4,500,000 sh
$66.4M

Congress trades in SLS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SLS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SLS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Biotech ETF
$127.7M position · as of 2026-06-30
1.2%
PROFUND VP BIOTECHNOLOGY
$564.8K position · as of 2026-06-30
1.2%
Amplify Etho Climate Leadership U.S. ETF
$1.9M position · as of 2026-06-30
1.0%
Virtus Biotech Clinical Trials Etf
$397.3K position · as of 2026-07-31
0.9%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$823.7K position · as of 2026-07-31
0.7%
iShares Micro-Cap ETF
$9.3M position · as of 2026-06-30
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
1
Phase 3
1 active
1
Not applicable
0 active
3
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 139 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SLS financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2023-01-01 to 2023-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term 2018-12-31 (91 months older than the period end) plus current 2018-12-31 (91 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-39.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-36.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-42.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.2B
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term 2018-12-31 (91 months older than the period end) plus current 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$0$1.0M
Operating income-$28.3M-$31.5M-$37.9M-$42.0M
Net income-$26.9M-$30.9M-$37.3M-$41.3M
EPS (diluted)-0.25-0.50-1.34-2.13
Operating cash flow-$28.4M-$35.4M-$31.4M-$23.8M
Cash$71.8M$13.9M$2.5M$17.1M
SEC XBRL, fiscal years, as known on 2026-10-27

SLS Stock Sonar score 5/7 axes

Find similar shapesCompare

SLS ranks highest on financial health (99th percentile) and institutional and government (80th), and lowest on growth (27th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
58
Inputs
  • Return on equity-39.6% · 60 pct, sector of 545
  • Return on assets-36.5% · 56 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-42.9% · 57 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
27
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoY+0.0% · 54 pct, sector of 40
Institutional and government
80
Inputs
  • Funds adding, latest quarter139 · 80 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
49
Inputs
  • Short interest, % of float+27.4% · 6 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.8% · 93 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies